Abstract
<jats:p>Abstract Objective Commercially available next-generation sequencing (NGS) platforms in China routinely adopt a lung cancer-derived tumor microenvironment (TME) subtyping signature from a European cohort to classify colorectal cancer (CRC), yet its diagnostic performance in Chinese CRC patients remains unvalidated. This study aimed to evaluate the subtyping efficiency of the lung cancer TME signature in a Chinese CRC cohort, screen CRC-specific immune mRNA biomarkers for TME subtyping, and explore the clinical utility of IRF1, CD8A and LAG3 for distinguishing immune-enriched (IE) and immune-desert plus fibrotic (D+F) subtypes. Methods A total of 87 FFPE CRC specimens with complete NGS and clinicopathological data were retrospectively enrolled, including 15 IE subtype and 72 D+F subtype patients. Thirty-one mRNA transcripts covering 13 immune-metabolic homeostasis genes and 18 immune checkpoint/infiltration-related genes were divided into two functional modules. Spearman correlation analysis was performed to assess co-expression patterns among candidate genes. Receiver operating characteristic (ROC) curves combined with five-fold cross-validation were used to compare the discriminatory efficacy of single-gene markers and the three-gene combined panel. Results Strong positive co-expression was observed between IRF1, CD8A and LAG3 (IRF1-CD8A: r=0.93; IRF1-LAG3: r=0.84; CD8A-LAG3: r=0.73). Nominal P-values indicated elevated expression of IRF1, CD8A and LAG3 in IE subtype, though no intergroup significance remained after Benjamini-Hochberg FDR correction, largely attributed to the limited sample size of IE cases. Single-gene ROC analysis showed AUC values of 0.763 (IRF1), 0.752 (CD8A) and 0.771 (LAG3), with LAG3 exhibiting the best individual discriminatory capacity. The three-gene combined panel yielded a cross-validated AUC of 0.717, inferior to single LAG3, due to severe collinearity that generated redundant predictive information. Conclusions The lung cancer-originated TME subtyping system cannot be directly extrapolated to Chinese CRC patients. LAG3 serves as a promising independent transcriptomic candidate marker for distinguishing CRC TME subtypes. The robust collinearity among IRF1, CD8A and LAG3 eliminates additional predictive benefits of the combined signature. Large independent multi-center Chinese CRC cohorts are required to construct population-specific immune transcriptomic biomarkers for standardized clinical NGS TME stratification.</jats:p>